ASPIVIX has signed distribution agreements with AGHealth and Titus Health Care to launch its Carevix cervical stabilizer across the UK and Benelux regions. The partnerships expand access to the MHRA and CE-marked device designed to reduce pain and bleeding during gynecological procedures.
The Swiss-based company’s Carevix device provides an alternative to traditional cervical tenaculum forceps, which are known to cause discomfort during procedures like IUD insertion and endometrial biopsies. Fear of pain during IUD insertion affects 30% to 45% of women globally, creating barriers to contraceptive adoption for an estimated 120 million women annually.
Clinical evidence from the ADVANCE Women Study, a randomized multicenter trial, demonstrated that Carevix achieved a 73% reduction in pain and 78% reduction in bleeding compared to standard tenaculum use during IUD placement. The device uses soft-suction technology to stabilize the cervix without traumatic grasping.
AGHealth will distribute Carevix in the UK, where Peterborough City Hospital became the first adopter in 2024 through ASPIVIX’s Ambassador Program. The program involved 21 centers across nine countries and showed 96% clinician satisfaction with ease of use and 94% overall patient satisfaction.
“At AGHealth, we focus on delivering forward-thinking, evidence-based solutions to clinicians. Carevix represents exactly the kind of innovation the UK market needs—offering a more dignified, pain-conscious option for gynaecological procedures that women undergo every day,” said Charlotte Barker, Director of AGHealth.
Titus Health Care will handle distribution across the Netherlands, Belgium, and Luxembourg. The Dutch company specializes in women’s health and fertility products, training over 2,000 healthcare professionals annually on contraceptive insertion techniques.
“At Titus Health Care, we are committed to offering solutions that truly improve the experience of women and their care providers. Carevix represents an important step toward more respectful, pain-conscious gynecology. We’re excited to bring this innovation to the Netherlands and Belgium, empowering clinicians with tools that reflect the care women deserve,” said Joep de Mönnink, Founder & Director of Titus Health Care.
Carevix has received FDA clearance, CE marking, MHRA approval, and ANVISA approval. The device was recognized as one of TIME Magazine’s Best Inventions in 2024 and received the 2022 iF Design Award.
“We’re proud to partner with Titus Health Care, whose reputation and reach in the Benelux region will help accelerate access to Carevix. Together, we’re enabling a shift toward gentler, more modern care, helping women make informed choices adopting IUD without the fear of pain and bleeding,” said Mathieu Horras, ASPIVIX CEO & Co-Founder.
The partnerships support ASPIVIX’s mission to modernize gynecological procedures by prioritizing patient comfort and dignity. The agreements position the company to address unmet needs in women’s healthcare where procedural pain remains a significant barrier to care access.
